Ribociclib Real-World Study in Early Breast Cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study observes people with early-stage hormone receptor positive, HER2-negative breast cancer who are taking ribociclib (Kisqali) with hormone therapy after surgery. It aims to see how well the treatment works and how safe it is in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your breast cancer is hormone receptor positive (estrogen or progesterone) and HER2-negative.
- You are currently taking ribociclib with hormone therapy after surgery, and started it within the last 6 months.
- Your breast cancer is stage II or III (early breast cancer, not spread to other parts of the body).
- You have not taken any other CDK4/6 inhibitor before (like palbociclib or abemaciclib).
- You are not taking part in any other clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
This trial checks how well people stick to their prescribed ribociclib (Kisqali) plus aromatase inhibitor treatment for early-stage, hormone-receptor-positive, HER2-negative breast cancer, and monitors for side effects. It focuses on making sure patients are safe and supported while taking their medication.
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
This study looks at how women and men with stage II or III HR+ HER2- breast cancer do when they start treatment with ribociclib or abemaciclib (combined with hormone therapy) after surgery. Researchers want to understand real-world experiences and results.
Hear when a new HR+/HER2- Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.